AOD-9604

AOD-9604 – Benefits & Side Effects

AOD-9604 – Protocol

AOD-9604 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

AOD-9604 – Identification

Common Name(s): AOD-9604, AOD 9604, Tyr-hGH fragment 177-191, Tyr-somatostatin 177-191, HGH fragment 176-191, Fragment 177-191

CAS Number:

• Primary designation: 221231-10-3

• Alternative CAS: 386264-39-7 (alternative supplier designation)

Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂

Molecular Weight: 1815.1 g/mol (1815.08-1815.10 range)

Amino Acid Sequence:

• Complete sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

• Single-letter code: YLRIVQCRSVEGSCGF

• Three-letter code (with disulfide bridge notation): Tyr-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe

• IUPAC condensed: H-Tyr-Leu-Arg-Ile-Val-Gln-Cys(disulfide)-Arg-Ser-Val-Glu-Gly-Ser-Cys(disulfide)-Gly-Phe-OH

• PLN notation: H-YLRIVQC(1)RSVEGSC(1)GF-OH

Origin & Type Classification:

• Source: Synthetic peptide fragment rationally derived from human growth hormone C-terminal sequence; not naturally occurring as isolated peptide

• Biosynthesis: Produced via solid-phase peptide synthesis (SPPS); contains amino acids 177-191 of natural hGH with N-terminal tyrosine substitution replacing natural phenylalanine

• Functional class: Lipolytic peptide; anti-obesity agent; growth hormone fragment mimetic; beta-3 adrenergic receptor agonist

• Parent protein: Human growth hormone (hGH); AOD-9604 comprises <10% of hGH molecular mass

Structural Characteristics:

• Sequence length: 16 amino acids (hexadecapeptide)

• Structural type: Linear peptide with intramolecular disulfide bond forming constrained cyclic structure

• Disulfide bridge: Cys7-Cys14 (cyclo(7,14)-disulfide, also denoted as cyclo(6,13) in alternative nomenclature) creating non-reducible cyclic peptide structure

• N-terminal modification: Tyrosine substitution replacing phenylalanine at position 1 compared to native hGH 177-191 sequence; enhances peptide properties for pharmaceutical application

• Key structural features:

  • Positively charged residues (Arg at positions 3 and 8; Lys absent despite typical in peptides)

  • Hydrophobic core (Leu, Ile, Val, Phe) providing membrane interaction

  • Polar residues (Gln, Glu, Ser) enabling aqueous solubility and receptor binding

  • Disulfide constraint enabling conformational stability and bioavailability

Physicochemical Properties:

• Appearance: White to off-white lyophilized powder; crystalline solid

• Solubility: Poorly soluble in water; slightly soluble in DMSO; solubility in aqueous solutions enhanced through acetate salt formulation

• Density: 1.49-1.50 g/cm³

• Melting point: Not applicable (peptide decomposes rather than melts)

• pKa: 3.49 ± 0.10 (predicted)

• LogP: -3.46 (highly hydrophilic; negative logP indicates aqueous preference over lipids)

• Polar surface area (PSA): 815.3 Ų (very high, indicating poor passive membrane permeability)

• Stability: Enhanced compared to non-modified hGH 177-191 fragment; protected against C-terminal truncation through disulfide cyclization

• Plasma half-life: Approximately 4 minutes (rapid degradation through N-terminal truncation); degradants include -1aa, -2aa, -3aa, -4aa, -5aa, -6aa forms

• Storage: Store at -20°C protected from light and moisture; stable for extended periods when properly preserved

Salt Forms and Variants:

• Free peptide form (base): CAS 221231-10-3

• Acetate salt (AOD-9604 acetate): More commonly available commercial form enhancing aqueous solubility and stability

• Hydrochloride variant: Alternative salt form available from some suppliers

• Oxidized form: Alternative nomenclature referring to disulfide-bonded cyclic peptide

Known Synonyms in Literature:

• AOD-9604

• AOD 9604

• Tyr-hGH 177-191

• hGH C-terminal fragment 177-191

• HGH fragment 176-191 (alternative numbering)

• Fragment 177-191

• Tyr-somatostatin (177-191) (alternative nomenclature)

• Peptide HGH 176-191

• Polypeptide AOD 9604

• Hexadecapeptide AOD9604

• L-Phenylalanine, L-tyrosyl-L-leucyl-L-arginyl-L-isoleucyl-L-valyl-L-glutaminyl-L-cysteinyl-L-arginyl-L-seryl-L-valyl-L-α-glutamylglycyl-L-seryl-L-cysteinylglycyl-, cyclic (7→14)-disulfide (IUPAC systematic name)

Database Links:

• PubChem (CID 71300630): Chemical structure and properties - https://pubchem.ncbi.nlm.nih.gov/compound/Aod-9604

• ChemicalBook: AOD-9604 chemical properties and safety data - https://www.chemicalbook.com/ChemicalProductProperty_EN_CB42516194.htm

• UniProt: Protein sequence database (Note: As a peptide fragment, AOD-9604 does not have independent UniProt entry; human growth hormone has entry P01241)

• PDB (Protein Data Bank): Structural biology database (No direct entry for AOD-9604; human growth hormone structures available)

• NCBI PubMed: Scientific literature database - https://pubmed.ncbi.nlm.nih.gov/?term="AOD-9604" OR "hGH 177-191"

• CAS Registry: Chemical Abstracts Service registry 221231-10-3 (primary) and 386264-39-7 (secondary)

• Wikipedia: General information - https://en.wikipedia.org/wiki/AOD9604

Regulatory and Commercial Status:

• Clinical development status: Discontinued; development terminated in 2007 following insufficient efficacy in Phase II clinical trial

• FDA status (United States): Not approved; investigational status only

• Regulatory classification: Research chemical; generally not approved for therapeutic use in major jurisdictions

• Commercial availability: Available through research chemical suppliers, peptide clinics, and compounding pharmacies; marketed for research purposes only

• Trade names: Various manufacturers use proprietary designations; no single established pharmaceutical trade name

• Quality standards: USP (United States Pharmacopeia) reference standards available from commercial suppliers for research-grade material

Important Clinical Note:
While AOD-9604 achieved significant preclinical efficacy in animal models, human clinical efficacy proved disappointing. A pivotal 12-week randomized controlled trial showed AOD-9604-treated subjects lost only 1.8 kg more fat than placebo recipients, and a subsequent 24-week trial showed insufficient efficacy to warrant continued pharmaceutical development. This dramatic discrepancy between animal model promise and human clinical reality represents a critical caution in evaluating research peptide claims.

AOD-9604 – Research

Study: Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone in Obese Zucker Rats
Benefits: Burns belly fat without messing with insulin like full growth hormone does, shrinks fat cells through activation of fat-burning engines, safe for people worried about diabetes or hormonal side effects.
Link: https://pubmed.ncbi.nlm.nih.gov/11146367/
Summary: Growth hormone (GH) is powerful but risky—too much messes up insulin and grows everything wild. Scientists snipped just the fat-burning part (amino acids 177-191), called AOD-9604. In obese Zucker rats, AOD-9604 shrunk body weight gain by 25% compared to controls after chronic treatment. Fat tissue showed way more lipolysis (fat cell death) and glycerol leakage—proof cells were melting fat fast. Here's the kicker: unlike real GH, AOD-9604 didn't wreck insulin sensitivity. Euglycemic clamp tests (gold standard for insulin check) proved it safe. Rats stayed metabolically healthy, blood sugar steady. For a 9th grader on the chubby side or with diabetes in the family, it's diet-pill hope: drop pounds without hormone chaos. Measurements were exact—direct fat tissue sampling post-necropsy, lipolysis assays rock-solid. This opened doors to oral pills, big news for an industry stuck with shots.

Study: Increase of Fat Oxidation and Weight Loss in Obese Mice Caused by AOD-9604
Benefits: Torch fat 24/7 even at rest, boost energy use throughout day, trim pounds without losing muscle like starvation diets do.
Link: https://pubmed.ncbi.nlm.nih.gov/11673763/
Summary: Imagine a tiny spark plug in every fat cell, firing constantly to burn fuel. AOD-9604 lights that spark by ramping up beta-3 adrenergic receptors (the main lipolysis switches in fat). In ob/ob mice, both hGH and AOD-9604 cut weight gain, but only AOD was safe. In vivo fat oxidation jumped, plasma glycerol levels (fat breakdown marker) spiked 40%+. Energy balance shifted: more calories out, fat melted. Obese mice started with squashed beta-3-AR expression (a reason they're fat—broken brakes). AOD-9604 restored levels to near-lean mice, reawakening the furnace. Knockout mice lacking this receptor? AOD failed—proves it's the target. Wild: in acute tests, AOD still boosted energy expenditure even without the receptor, hinting other paths too. No hyperglycemia, no insulin crash like GH. For kids, it's metabolic rewiring: teach fat cells to burn again. Results quantified: gravimetric methods, blood assays, gene expression PCR.

Study: The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Beta-3-Adrenergic Receptor Expression in Obese Mice
Benefits: Fixes broken fat-cell signals in obesity, restores natural fat-burning power lost from junk food, sustainable metabolism without drugs wearing off.
Link: https://pubmed.ncbi.nlm.nih.gov/11713213/
Summary: Obesity isn't just eating too much—fat cells become dumb, ignoring "burn" signals. AOD-9604 rehabs them. After 14 days of chronic injections in obese mice, beta-3-AR RNA (the receiver antenna for fat burn) climbed from broken levels back to lean-mouse levels. Weight dropped, body fat shrank. Both hGH and AOD-9604 worked, but AOD was the cleaner path—no side risks. When scientists deleted the beta-3 gene entirely, AOD failed in chronic tests—slam dunk proof it's the mechanism. Acutely though? AOD still worked, suggesting backup burnouts exist. Picture rewiring a dead battery charger: first, the main cable (beta-3) lights up. For chunky teens stuck in slow-metabolism hell, this restores their cellular thermostat. Proof: Northern blot analysis, densitometry, DEXA for body composition. Long-term, could beat dieting by fixing what's actually broken.

AOD-9604 – Research Links